Work Here?
Azurity Pharmaceuticals
Work Here?
Develops specialized formulations of medicines
Azurity Pharmaceuticals
Work Here?
Develops specialized formulations of medicines
About Azurity Pharmaceuticals
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
Growth Equity (Venture Capital)
Total Funding
$182.2M
Headquarters
Woburn, Massachusetts
Founded
2000
Overview
Azurity Pharmaceuticals develops specialized formulations of existing medicines to meet the needs of patients who are often overlooked by other pharmaceutical companies. They focus on creating new dose forms, such as oral suspensions, that are easier to administer and absorb, particularly for those who have difficulty swallowing pills or need precise dosing. This approach enhances patient compliance and addresses gaps in the pharmaceutical market. Azurity's products cover a wide range of therapeutic areas, including cardiovascular, central nervous system, endocrine, gastrointestinal, anti-infective, and oncology medicines. They generate revenue through the sale of FDA-approved proprietary medicines, ensuring safety and efficacy. Azurity's goal is to provide high-quality, innovative medicines that improve patient outcomes and serve the needs of diverse healthcare providers, hospitals, and pharmacies.
Simplify's Take
What believers are saying
- Growing demand for personalized medicine aligns with Azurity's specialized dose forms.
- Increasing chronic diseases boost need for Azurity's innovative drug delivery systems.
- FDA's focus on novel formulations benefits Azurity's product pipeline.
What critics are saying
- Product recalls, like Zenzedi's, can damage brand reputation and cause financial losses.
- Integration challenges from Slayback Pharma acquisition may disrupt operations.
- Reliance on FDA approvals means regulatory delays could impact product launches.
What makes Azurity Pharmaceuticals unique
- Azurity focuses on innovative dose forms for overlooked patient needs.
- Their FDA-approved products ensure safety and efficacy in specialized formulations.
- Azurity's acquisition of Slayback Pharma enhances its development and launch capabilities.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$182.2M
Above
Industry Average
Funded Over
0 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Hybrid Work Options
Professional Development Budget
Tuition Reimbursement
Wellness Program
Company News
WOBURN, Mass., Dec. 12, 2024 /PRNewswire/ -- Azurity Pharmaceuticals announced today the availability of Azmiro™, the first and only FDA-approved prefilled testosterone cypionate injection. Azmiro is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. "Azurity's purpose is to serve overlooked patients by developing innovative dose forms and formulations to serve unmet needs," said Richard Blackburn, CEO of Azurity Pharmaceuticals. "The commercial availability of Azmiro offers a convenient prefilled option for healthcare providers administering testosterone to patients.". Testosterone cypionate intramuscular injections are commonly used as a testosterone replacement therapy for patients with low testosterone by drawing up testosterone cypionate doses from a vial, then administering with a syringe
WOBURN, Mass., Dec. 12, 2024 /PRNewswire/ - Azurity Pharmaceuticals announced today the availability of Azmiro(TM), the first and only FDA-approved prefilled testosterone cypionate injection.
WOBURN, Mass., May 6, 2024 /PRNewswire/ -- Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products to serve the needs of overlooked patients, announced today that the U.S. Food and Drug Administration (FDA) has approved Myhibbin™, the only ready-to-use mycophenolate mofetil oral suspension. Mycophenolate mofetil is an antimetabolite immunosuppressant used to protect a donated organ from being rejected from the body's immune response. In 2023, there were over 46,000 transplants in the US and these patients need to take medication every day to fight against rejection. Myhibbin is indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart, or liver transplants, in combination with other immunosuppressants."We are very pleased that adult and pediatric organ transplant recipients will soon have access to the only FDA-approved ready-to-use oral liquid formulation of mycophenolate," said Richard Blackburn, CEO of Azurity Pharmaceuticals. "Patients are our priority, and our purpose is to bring them new formulations that help them benefit from established medicines
Azurity Pharmaceuticals issued a recall for attention-deficit/hyperactivity disorder (ADHD) medication dextroamphetamine sulfate (Zenzedi) following the discovery of a potential mix-up in pill packaging, according to CNN.
Azurity Pharmaceuticals, Inc. announced the recall of one lot (F230169A) of Zenzedi CII (dextroamphetamine sulfate tablets, USP) 30 milligrams on Wednesday, which the U.S. Food and Drug Administration (FDA) put on its website on Thursday.
Azurity Pharmaceuticals is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Azurity Pharmaceuticals
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
Growth Equity (Venture Capital)
Total Funding
$182.2M
Headquarters
Woburn, Massachusetts
Founded
2000
Azurity Pharmaceuticals is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today